Humacyte (HUMA) Change in Account Payables (2020 - 2026)

Humacyte (HUMA) has 7 years of Change in Account Payables data on file, last reported at -$362000.0 in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$362000.0, down 155.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$42000.0 (down 102.56% YoY), and the FY2025 annual result was $973000.0, up 149.59% from the prior year.
• Change in Account Payables climbed to -$362000.0 in Q1 2026 per HUMA's latest filing, from -$4.2 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $3.5 million in Q4 2023 and troughed at -$4.2 million in Q4 2025.
• A 5-year average of $173588.2 and a median of $526000.0 in 2023 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2024: Change in Account Payables soared 5183.33% in 2022, then slumped 1086.29% in 2024.
• A 5-year view of Change in Account Payables shows it stood at -$1.5 million in 2022, then jumped by 335.7% to $3.5 million in 2023, then plunged by 169.25% to -$2.4 million in 2024, then slumped by 70.74% to -$4.2 million in 2025, then soared by 91.3% to -$362000.0 in 2026.
• Business Quant data shows HUMA's Change in Account Payables at -$362000.0 in Q1 2026, -$4.2 million in Q4 2025, and $3.0 million in Q3 2025.